{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:05:47Z","timestamp":1795176347329,"version":"4.10.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017346","name":"Nippon Boehringer Ingelheim Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Antifibrotics have been approved for use in many countries, including Japan, based on the results of several phase III clinical trials in patients with IPF, SSc-ILD, and PPF, which showed slower lung function decline with antifibrotic treatment. There is a paucity of information on the real-world use of antifibrotics in clinical practice.\n<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Baseline characteristics, comorbidities, and drugs used prior to and concomitant with antifibrotics were collected for patients with IPF, SSc-ILD, and PPF using a health insurance claims database in Japan from 1 January 2013 to 30 June 2023. Descriptive statistics were generated for all study variables.\n<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This study included 657 nintedanib users with IPF; 418 pirfenidone users with IPF; 4160 nintedanib users with PPF; 18,403 users of glucocorticoids\/immunosuppressants for ILD treatment with PPF; 676 nintedanib users with SSc-ILD; and 698 users of glucocorticoids\/immunosuppressants for ILD treatment with SSc-ILD. At index, pirfenidone users with IPF were the oldest (mean [SD] 74.8 [7.3] years), and nintedanib users with SSc-ILD were the youngest (mean [SD] 65.6 [11.7] years). In nintedanib users with IPF, 76.7% were prescribed nintedanib as monotherapy, and 75.6% of pirfenidone users were prescribed pirfenidone, as monotherapy. In patients with IPF, 75.2% were prescribed nintedanib, and 76.1% were prescribed pirfenidone, as first-line therapy. In patients with SSc-ILD, 34.9% were prescribed nintedanib as monotherapy for ILD treatment, and 38.6% as first-line therapy. Approximately half of patients with PPF were prescribed nintedanib concomitantly with other glucocorticoids\/immunosuppressant drugs, and after one or more glucocorticoids\/immunosuppressant drugs. The most common concomitant drug in all patient groups was glucocorticoids. In patients with IPF, 18.6% of nintedanib users and 18.2% of pirfenidone users were prescribed glucocorticoids concomitantly. Concomitant glucocorticoid use was 52.7% for nintedanib users with SSc-ILD, and 44.1% for nintedanib users with PPF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These results provide real-world evidence of antifibrotic use in clinical practice. Most patients with IPF were prescribed antifibrotics as monotherapy for ILD treatment whereas antifibrotics were used concomitantly with glucocorticoids\/immunosuppressants in many patients with SSc-ILD and PPF. While most patients with IPF were prescribed antifibrotics as first-line therapy, patients with SSc-ILD and PPF were more likely to be prescribed nintedanib as second-line or later-line treatment after glucocorticoids\/immunosuppressants.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12890-025-03713-x","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T08:31:16Z","timestamp":1747902676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-5459","authenticated-orcid":false,"given":"Yasuhiro","family":"Kondoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6456-2825","authenticated-orcid":false,"given":"Tomohiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4704-5435","authenticated-orcid":false,"given":"Hana","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haikun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"150","key":"3713_CR1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, Skowasch D, Park JS, Poonyagariyagorn HK, Wuyts W, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150): 180076.","journal-title":"Eur Respir Rev"},{"issue":"7","key":"3713_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","volume":"2","author":"G Raghu","year":"2014","unstructured":"Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001\u201311. Lancet Respir Med. 2014;2(7):566\u201372.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3713_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, Tomassetti S, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925\u201334.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3713_CR4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"3713_CR5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"22","key":"3713_CR6","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"4","key":"3713_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1183\/09031936.00005209","volume":"35","author":"H Taniguchi","year":"2010","unstructured":"Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821\u20139.","journal-title":"Eur Respir J"},{"issue":"26","key":"3713_CR8","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"key":"3713_CR9","doi-asserted-by":"crossref","unstructured":"King Talmadge E, Bradford Williamson Z, Castro-Bernardini S, Fagan Elizabeth A, Glaspole I, Glassberg Marilyn K, Gorina E, Hopkins Peter M, Kardatzke D, Lancaster L, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.\u00a0N Engl J Med. 2014;370(22):2083\u201392.","DOI":"10.1056\/NEJMoa1402582"},{"key":"3713_CR10","unstructured":"Ministry of Health Labour and Welfare. Report on the deliberation results of pirfenidone (indication: idiopathic pulmonary fibrosis). 2008. https:\/\/www.pmda.go.jp\/files\/000153687.pdf. Accessed 19 Aug 2024."},{"key":"3713_CR11","unstructured":"Ministry of Health Labour and Welfare. Report on the deliberation results for nintedanib ethanesulfonate (indication: idiopathic pulmonary fibrosis). 2015. https:\/\/www.pmda.go.jp\/files\/000214531.pdf. Accessed 19 Aug 2024."},{"key":"3713_CR12","unstructured":"Boehringer Ingelheim. FDA Approves Boehringer Ingelheim\u2019s OFEV\u00ae (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis. https:\/\/www.boehringer-ingelheim.com\/us\/media\/press-releases\/fda-approves-ofev-nintedanib-treat-ipf-bi-us. Accessed 12 Nov 2024."},{"key":"3713_CR13","unstructured":"European Medicines Agency. Ofev\u00ae (nintedanib) European Commission decision. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ofev. Accessed 12 Nov 2024."},{"key":"3713_CR14","unstructured":"Genentech. FDA Approves Medicine for Idiopathic Pulmonary Fibrosis. https:\/\/www.gene.com\/media\/news-features\/medicine-fda-approved-for-idiopathic-pulmonary-fibrosis. Accessed 12 Nov 2024."},{"key":"3713_CR15","unstructured":"Roche. Esbriet (pirfenidone). https:\/\/www.roche.com\/solutions\/pharma\/productid-6c2ee193-7a4e-4d73-b48d-6c8fa1179a11. Accessed 12 Nov 2024."},{"key":"3713_CR16","unstructured":"Ministry of Health Labour and Welfare. Report on the deliberation results for nintedanib ethanesulfonate (indication: progressive fibrosing interstitial lung disease). 2020. https:\/\/www.pmda.go.jp\/files\/000243773.pdf. Accessed 19 Aug 2024."},{"key":"3713_CR17","unstructured":"Boehringer Ingelheim. European Commission approves third nintedanib indication in pulmonary fibrosis. https:\/\/www.boehringer-ingelheim.com\/human-health\/lung-diseases\/scleroderma\/ecapprovalnintedanibildpf. Accessed 12 Nov 2024."},{"key":"3713_CR18","unstructured":"Boehringer Ingelheim. European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). https:\/\/www.boehringer-ingelheim.com\/human-health\/lung-diseases\/scleroderma\/europeancommissionapprovesnintedanibssc-ild. Accessed 12 Nov 2024."},{"key":"3713_CR19","unstructured":"Boehringer Ingelheim. FDA approves Ofev\u00ae as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD. https:\/\/www.boehringer-ingelheim.com\/human-health\/lung-diseases\/scleroderma\/fda-approves-nintedanib-ssc-ild. Accessed 12 Nov 2024."},{"key":"3713_CR20","unstructured":"Boehringer Ingelheim. FDA approves Ofev\u00ae as first treatment for chronic fibrosing ILDs with a progressive phenotype. https:\/\/www.boehringer-ingelheim.com\/us\/media\/press-releases\/fda-approves-ofev-first-treatment-chronic-fibrosing-ilds-progressive-phenotype. Accessed 12 Nov 2024."},{"issue":"2","key":"3713_CR21","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et al. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3-19.","journal-title":"Am J Respir Crit Care Med."},{"issue":"8","key":"3713_CR22","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/art.42861","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, Khanna D, Guyatt G, Mirza RD, Aggarwal R, et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.\u00a0Arthritis Rheumatol. 2024;76(8):1182\u2013200.","journal-title":"Arthritis & Rheumatology"},{"issue":"2","key":"3713_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","volume":"209","author":"G Raghu","year":"2024","unstructured":"Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, Barnes H, Adegunsoye A, Azuma A, Chung L, et al. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024;209(2):137\u201352.","journal-title":"Am J Respir Crit Care Med"},{"key":"3713_CR24","unstructured":"The Japanese Respiratory Society. 2020 The Guide for the Diagnosis and Treatment of Interstitial Lung Disease Associated with Connective Tissue Disease. https:\/\/www.jrs.or.jp\/publication\/jrs_guidelines\/20200630142610.html. Accessed 19 Aug 2024."},{"key":"3713_CR25","unstructured":"The Japanese Respiratory Society. Idiopathic Interstitial Pneumonia Diagnosis and Treatment Guide 2022 (Revised 4th Edition). https:\/\/www.jrs.or.jp\/publication\/jrs_guidelines\/20220221092117.html. Accessed 25 Sept 2024."},{"key":"3713_CR26","unstructured":"The Japanese Respiratory Society. Japanese Guideline for the Treatment of Idiopathic Pulmonary Fibrosis 2023 (Revised 2nd Edition). https:\/\/www.jrs.or.jp\/publication\/jrs_guidelines\/20230417134321.html. Accessed 25 Sept 2024."},{"key":"3713_CR27","unstructured":"Medical Data Vision. About MDV database. https:\/\/www.mdv.co.jp\/about\/. Accessed 19 Aug 2024."},{"issue":"4","key":"3713_CR28","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.resinv.2024.05.005","volume":"62","author":"Y Kondoh","year":"2024","unstructured":"Kondoh Y, Ito T, Saito K, Bao H, Sakamoto W. Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database. Respir Investig. 2024;62(4):702\u20139.","journal-title":"Respir Investig"},{"issue":"1","key":"3713_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12931-022-01938-6","volume":"23","author":"Y Kondoh","year":"2022","unstructured":"Kondoh Y, Suda T, Hongo Y, Yoshida M, Hiroi S, Iwasaki K, Takeshima T, Homma S. Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis. Respir Res. 2022;23(1):24.","journal-title":"Respir Res"},{"issue":"1","key":"3713_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12931-021-01695-y","volume":"22","author":"I Glaspole","year":"2021","unstructured":"Glaspole I, Bonella F, Bargagli E, Glassberg MK, Caro F, Stansen W, Quaresma M, Orsatti L, Bendstrup E. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respir Res. 2021;22(1):125.","journal-title":"Respir Res"},{"issue":"4","key":"3713_CR31","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1007\/s12325-022-02411-y","volume":"40","author":"T Ogura","year":"2023","unstructured":"Ogura T, Inoue Y, Azuma A, Homma S, Kondoh Y, Tanaka K, Ochiai K, Sugiyama Y, Nukiwa T. Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan. Adv Ther. 2023;40(4):1474\u201393.","journal-title":"Adv Ther"},{"issue":"1","key":"3713_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41232-024-00345-2","volume":"44","author":"Y Nishioka","year":"2024","unstructured":"Nishioka Y, Araya J, Tanaka Y, Kumanogoh A. Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease.\u00a0Inflamm Regen.\u00a02024;44(1):34.","journal-title":"Inflammation and Regeneration"},{"key":"3713_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838449","volume":"13","author":"FE Herrmann","year":"2022","unstructured":"Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol. 2022;13:838449.","journal-title":"Front Pharmacol"},{"issue":"23","key":"3713_CR34","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","volume":"386","author":"L Richeldi","year":"2022","unstructured":"Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM, et al. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2022;386(23):2178\u201387.","journal-title":"N Engl J Med"},{"key":"3713_CR35","doi-asserted-by":"crossref","unstructured":"Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS et al. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respir Res. 2023;10(1):e001580.","DOI":"10.1136\/bmjresp-2022-001580"},{"key":"3713_CR36","doi-asserted-by":"crossref","unstructured":"Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Gordat M, Liu Y et al. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF). BMJ Open Respir Res.\u00a02023;10(1):e001563.","DOI":"10.1136\/bmjresp-2022-001563"},{"key":"3713_CR37","unstructured":"Boehringer Ingelheim. Boehringer\u2019s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER\u2122-IPF study. https:\/\/www.boehringer-ingelheim.com\/human-health\/lung-diseases\/pulmonary-fibrosis\/nerandomilast-primary-endpoint-phase-3-fibroneer-ipf-met. Accessed 12 Nov 2024."},{"key":"3713_CR38","unstructured":"Boehringer Ingelheim. Boehringer\u2019s nerandomilast meets primary endpoint in Phase III study FIBRONEER\u2122-ILD, in progressive pulmonary fibrosis. https:\/\/www.boehringer-ingelheim.com\/human-health\/lung-diseases\/pulmonary-fibrosis\/nerandomilast-primary-endpoint-phase-3-fibroneer-ild-pulmonary-fibrosis. Accessed 28 Mar 2025."},{"key":"3713_CR39","unstructured":"The Japanese Respiratory Society. Japanese Guideline for the Treatment of Idiopathic Pulmonary Fibrosis 2017. https:\/\/www.jrs.or.jp\/publication\/jrs_guidelines\/20170101165833.html. Accessed 25 Sept 2024."},{"issue":"6","key":"3713_CR40","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3713_CR41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","volume":"59","author":"Y Kondoh","year":"2021","unstructured":"Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, Anraku M, Enomoto N, Fujii T, Fujisawa T, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig. 2021;59(6):709\u201340.","journal-title":"Respir Investig"},{"key":"3713_CR42","unstructured":"Vonk M, Distler O, Furst D, Hachulla E, Johnson S, Assassi S, Meng L, Quaresma M, Alves M, Clerisme-Beaty E et al. Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use [abstract]. Arthritis Rheumatol 2019; 71 (suppl 10). https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-nintedanib-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-subgroup-analysis-of-the-senscis-trial-by-corticosteroid-use\/ Accessed 15 October 2024."},{"key":"3713_CR43","unstructured":"The Japanese Respiratory Society. Hypersensitivity Pneumonitis Treatment Guidelines 2022. https:\/\/www.jrs.or.jp\/publication\/jrs_guidelines\/20220411100000.html Accessed 25 September 2024."},{"issue":"10","key":"3713_CR44","first-page":"753","volume":"44","author":"T Ito","year":"2023","unstructured":"Ito T, Shibuya A, Saisho H. Safety and Tolerability of Nintedanib in Japanese Patients with Progressive Fibrosing Interstitial Lung Diseases. First Interim Report of a 2-Year Post-marketing Surveillance. Therapeutic Research. 2023;44(10):753\u201364.","journal-title":"Therapeutic Research."},{"issue":"2","key":"3713_CR45","first-page":"00423","volume":"9","author":"L Raman","year":"2022","unstructured":"Raman L, Stewart I, Barratt SL, Chua F, Chaudhuri N, Crawshaw A, Gibbons M, Hogben C, Hoyles R, Kouranos V, et al. Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study. ERJ Open Res. 2022;9(2):00423\u20132022.","journal-title":"ERJ Open Res"},{"key":"3713_CR46","doi-asserted-by":"crossref","unstructured":"Dixon G, Hague S, Mulholland S, Adamali H, Khin AMN, Thould H, Connon R, Minnis P, Murtagh E, Khan F, et al. Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK. ERJ Open Res. 2024;10(1):00529\u20132023.","DOI":"10.1183\/23120541.00529-2023"},{"key":"3713_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152312","volume":"64","author":"PA Juge","year":"2024","unstructured":"Juge PA, Hayashi K, McDermott GC, Vanni KMM, Kowalski E, Qian G, Bade K, Saavedra A, Dieude P, Dellaripa PF, et al. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease. Semin Arthritis Rheum. 2024;64:152312.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"3713_CR48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17476348.2024.2375420","volume":"18","author":"M Naqvi","year":"2024","unstructured":"Naqvi M, Hannah J, Lawrence A, Myall K, West A, Chaudhuri N. Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances. Expert Rev Respir Med. 2024;18(6):397\u2013407.","journal-title":"Expert Rev Respir Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03713-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T08:31:35Z","timestamp":1747902695000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03713-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3713"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03713-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was designed, conducted, and reported using best practice guidelines, with Institutional Review Board (IRB) approval from the Takahashi Clinic Ethics Committee on December 5, 2023 (IRB approval number: LNW00207). Hence, all objectives and methods were pre-specified and executed according to the study protocol. This study used anonymised processed information from the Medical Data Vision database and therefore informed consent to participate was deemed unnecessary according to Ethical Guidelines for Medical and Biological Research Involving Human Subjects (2023 Revision) by the Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, and Ministry of Economy, Trade and Industry, in Japan. In addition, as this study used anonymised processed information from the Medical Data Vision database, the Declaration of Helsinki is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yasuhiro Kondoh has received consulting fees from Asahi Kasei Pharma Corp, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd., Healios K.K., Janssen Pharmaceutical KK, Shionogi Co, Ltd., and Taiho Pharmaceutical Co., Ltd., and serves on speaker bureaus for Asahi Kasei Pharma Corp, Boehringer Ingelheim, Eisai Co, Ltd, Bristol Myers Squibb, Janssen Pharmaceutical K.K., KYORIN Pharmaceutical Co, Ltd, Mitsubishi Tanabe Pharma, NIPPON SHINYAKU CO., LTD, Novartis Pharma KK, Shionogi Co, Ltd., and Teijin Pharma Ltd. Tomohiro Ito, Hana Kimura, and Haikun Bao are employees of Boehringer Ingelheim. Masataka Kuwana has received consulting fees, speaking fees, and research grants from AbbVie, argenx, Asahi Kasei, AstraZeneca, Astellas, Boehringer Ingelheim, Chugai, Corbus, Eisai, GlaxoSmithKline, Horizon, Janssen, Kissei, MBL, Mitsubishi Tanabe, Mochida, Nippon Shinyaku, Ono Pharmaceuticals, Pfizer, and Taisho. Tomohiro Ito, Hana Kimura, and Haikun Bao are employees of Boehringer Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}